However, inhibition of FOXM1 may have or not have an inhibitory effect on other non-MLL-r AMLs, indicating that personalized treatment of AML patients with FOXM1 inhibitors needs to be considered. This evidence concerns the gene KMT2A and acute myeloid leukemia.